The latest price target for Gilead Sciences (NASDAQ:GILD) was reported by Morgan Stanley on July 8, 2026. The analyst firm set a price target for $166.00 expecting GILD to rise to within 12 months (a possible 23.60% upside). 45 analyst firms have reported ratings in the last year.

The latest analyst rating for Gilead Sciences (NASDAQ:GILD) was provided by Morgan Stanley, and Gilead Sciences maintained their overweight rating.

The last upgrade for Gilead Sciences Inc happened on July 6, 2026 when HSBC raised their price target to $155. HSBC previously had a hold for Gilead Sciences Inc.

The last downgrade for Gilead Sciences Inc happened on November 8, 2024 when Maxim Group changed their price target from N/A to N/A for Gilead Sciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gilead Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gilead Sciences was filed on July 8, 2026 so you should expect the next rating to be made available sometime around July 8, 2027.

While ratings are subjective and will change, the latest Gilead Sciences (GILD) rating was a maintained with a price target of $168.00 to $166.00. The current price Gilead Sciences (GILD) is trading at is $134.30, which is out of the analyst’s predicted range.